Evidence map›Paper›PMID 32702719›Full record

ArticleResearch square2020

COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms.

Robert W Malone, Philip Tisdall, Philip Fremont-Smith, Yongfeng Liu, Xi-Ping Huang, Kris M White, Lisa Miorin, Elena Moreno Del Olmo, Assaf Alon, Elise Delaforge and 12 more

Open access · goldAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in Research square, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 27 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors at 8 institutions in 3 countries.

Robert W MaloneRW Malone MD LLC, Madison, VA.ORCID 0000-0003-0340-7490
Philip TisdallMedical School Companion LLC, Marco Island, FL.
Philip Fremont-SmithMIT Lincoln Laboratory, Lexington, MA.
Yongfeng LiuDepartment of Pharmacology, University of North Carolina, Chapel Hill, Chapel Hill, NC.
Xi-Ping HuangDepartment of Pharmacology, University of North Carolina, Chapel Hill, Chapel Hill, NC.
Kris M WhiteDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY.
Lisa MiorinGlobal Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
Elena Moreno Del OlmoGlobal Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
Assaf AlonDepartment of Biological Chemistry and Molecular Pharmacology, Blavatnik Institute, Harvard Medical School, Boston, MA.
Elise DelaforgeMcGill University, Department of Chemistry, Montreal, Quebec, Canada.
Christopher D HenneckerMcGill University, Department of Chemistry, Montreal, Quebec, Canada.
Guanyu WangMcGill University, Department of Chemistry, Montreal, Quebec, Canada.
Joshua PottelMolecular Forecaster Inc, Montreal, Quebec, Canada.
Nora SmithMIT Lincoln Laboratory, Lexington, MA.
Julie M HallFrank H. Netter MD School of Medicine - Quinnipiac University, Hamden, CT.
Gideon ShapiroPharmorx LLC, Gainesville, FL.
Anthony MittermaierMcGill University, Department of Chemistry, Montreal, Quebec, Canada.
Andrew C KruseDepartment of Biological Chemistry and Molecular Pharmacology, Blavatnik Institute, Harvard Medical School, Boston, MA.
Adolfo García-SastreDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY,Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
Bryan L RothDepartment of Pharmacology, University of North Carolina, Chapel Hill, Chapel Hill, NC.
Jill Glasspool-MaloneRW Malone MD LLC, Madison, VA.
Darrell O RickeMIT Lincoln Laboratory, Lexington, MA.
Quinnipiac University · USIcahn School of Medicine at Mount Sinai · USMcGill University · CAMIT Lincoln Laboratory · USUniversity of North Carolina at Chapel Hill · USHarvard University · USMalone University · USUniversity College London · GB

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
SARS-CoV adaptations through a Systems Biology Lens (SYBIL)U19AI135972 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Adolfo Garcia-Sastre · 2018 to 2026
$27.2M
NCATS NIH HHS UL1 TR001863NIAID NIH HHS HHSN272201400008CNIAID NIH HHS U19 AI135972
6 · The paper itself

Abstract

SARS-CoV-2 infection is required for COVID-19, but many signs and symptoms of COVID-19 differ from common acute viral diseases. Currently, there are no pre- or post-exposure prophylactic COVID-19 medical countermeasures. Clinical data suggest that famotidine may mitigate COVID-19 disease, but both mechanism of action and rationale for dose selection remain obscure. We explore several plausible avenues of activity including antiviral and host-mediated actions. We propose that the principal famotidine mechanism of action for COVID-19 involves on-target histamine receptor H

Indexed as

COVID-19FamotidineGPCRHistamineMast Cell

Identifiers

PMID32702719
PMCPMC7336703
OpenAlexW3154166937

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.